4-Hydroxyisoleucine improves insulin resistance in HepG2 cells by decreasing TNF-α and regulating the expression of insulin signal transduction proteins

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6555-6560

  Gao, Feng ^a   Jian, Liumeng ^a   Zafar, Mohammad Ishraq ^a   Du, Wen ^a   Cai, Qin ^a   Shafqat, Raja Adeel ^a   Lu, Furong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

4 hydroxyisoleucine; Insulin receptor substrate 1; Insulin receptor substrate 2; Insulin resistance; Phosphorylation of insulin receptor substrate 1 (Ser307); TNF converting enzyme tissue inhibitor of metalloproteinase 3; Tumor necrosis factor

Indexed keywords

4 HYDROXYISOLEUCINE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; SERINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; 4-HYDROXYISOLEUCINE; ADAM PROTEIN; ADAM17 PROTEIN, HUMAN; GLUCOSE; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; IRS2 PROTEIN, HUMAN; ISOLEUCINE; SLC2A4 PROTEIN, HUMAN; TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TRANSPORT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; ISOLATION AND PURIFICATION; METABOLISM; PHOSPHORYLATION; TRIGONELLA;

ADAM PROTEINS; ADAM17 PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HEP G2 CELLS; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; ISOLEUCINE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRIGONELLA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943604479     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4298     Document Type: Article

References (34)

1. Cordain L, Eades MR and Eades MD: Hyperinsulinemic diseases of civilization: More than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol 136: 95-112, 2003.
2. Xie W, Wang W, Su H, Xing D, Pan Y and Du L: Effect of ethanolic extracts of Ananas comosus L. leaves on insulin sensitivity in rats and HepG2. Comp Biochem Physiol C Toxicol Pharmacol 143: 429-435, 2006.
3. Peraldi P, Hotamisligil GS, Buurman WA, White MF and Spiegelman BM: Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271: 13018-13022, 1996.
4. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, et al: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733-736, 1997.
5. Bu R, Borysenko CW, Li Y, Cao L, Sabokbar A and Blair HC: Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 33: 760-770, 2003.
6. Moreira AP, Dias-Melicio LA, Peraçoli MT, Calvi SA and Victoriano de Campos Soares AM: Killing of Paracoccidioides brasiliensis yeast cells by IFN-gamma and TNF-alpha activated murine peritoneal macrophages: Evidence of H (2)O (2) and NO effector mechanisms. Mycopathologia 166: 17-23, 2008.
7. Takahashi E, Okumura A, Unoki-Kubota H, Hirano H, Kasuga M and Kaburagi Y: Differential proteome analysis of serum proteins associated with the development of type 2 diabetes mellitus in the KK-A(y) mouse model using the iTRAQ technique. J Proteomics 84: 40-51, 2013.
8. Saghizadeh M, Ong JM, Garvey WT, Henry RR and Kern PA: The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97: 1111-1116, 1996.
9. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K and Yano Y: Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83: 859-862, 1998.
10. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A and White MF: Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107: 181-189, 2001.
11. del Aguila LF, Claffey KP and Kirwan JP: TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol 276: E849-E855, 1999.
12. Krogh-Madsen R, Plomgaard P, Møller K, Mittendorfer B and Pedersen BK: Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 291: E108-E114, 2006.
13. Tang ZY, Loss G, Carmody I and Cohen AJ: TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation 82: 1518-1523, 2006.
14. Narender T, Puri A, Shweta, Khaliq T, Saxena R, Bhatia G and Chandra R: 4-hydroxyisoleucine an unusual amino acid as antidyslipidemic and antihyperglycemic agent. Bioorg Med Chem Lett 16: 293-296, 2006.
15. Jetté L, Harvey L, Eugeni K and Levens N: 4-Hydroxyisoleucine: A plant-derived treatment for metabolic syndrome. Curr Opin Investig Drugs 10: 353-358, 2009.
16. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baissac Y, Fernandez-Alvarez J, Gross R, Roye M, Leconte A, Gomis R and Ribes G: 4-Hydroxyisoleucine: A novel amino acid potentiator of insulin secretion. Diabetes 47: 206-210, 1998.
17. Haefelé C, Bonfils C and Sauvaire Y: Characterization of a dioxygenase from Trigonella foenum-graecum involved in 4-hydroxyisoleucine biosynthesis. Phytochemistry 44: 563-566, 1997.
18. Broca C, Manteghetti M, Gross R, Baissac Y, Jacob M, Petit P, Sauvaire Y and Ribes G: 4-Hydroxyisoleucine: Effects of synthetic and natural analogues on insulin secretion. Eur J Pharmacol 390: 339-345, 2000.
19. Broca C, Breil V, Cruciani-Guglielmacci C, Manteghetti M, Rouault C, Derouet M, Rizkalla S, Pau B, Petit P, Ribes G, et al: Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat. Am J Physiol Endocrinol Metab 287: E463-E471, 2004.
20. Savage DB, Petersen KF and Shulman GI: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 45: 828-833, 2005.
21. Haeri MR, Izaddoost M, Ardekani MR, Nobar MR and White KN: The effect of fenugreek 4-hydroxyisoleucine on liver function biomarkers and glucose in diabetic and fructose-fed rats. Phytother Res 23: 61-64, 2009.
22. Henkel J, Neuschäfer-Rube F, Pathe-Neuschäfer-Rube A and Püschel GP: Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 50: 781-790, 2009.
23. Ogawa J, Kodera T, Smirnov SV, Hibi M, Samsonova NN, Koyama R, Yamanaka H, Mano J, Kawashima T, Yokozeki K and Shimizu S: A novel L-isoleucine metabolism in Bacillus thuringiensis generating (2S,3R,4S)-4-hydroxyisoleucine, a potential insulinotropic and anti-obesity amino acid. Appl Microbiol Biotechnol 89: 1929-1938, 2011.
24. Zhang WY, Lee JJ, Kim IS, Kim Y, Park JS and Myung CS: 7-O-methylaromadendrin stimulates glucose uptake and improves insulin resistance in vitro. Biol Pharm Bull 33: 1494-1499, 2010.
25. Khan AH and Pessi JE: Insulin regulation of glucose uptake: A complex interplay of intracellular signalling pathways. Diabetologia 45: 1475-1483, 2002.
26. Wang Q, Somwar R, Bilan PJ, Liu Z, Jin J, Woodgett JR and Klip A: Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol Cell Biol 19: 4008-4018, 1999.
27. Miura A, Ishizuka T, Kanoh Y, Ishizawa M, Itaya S, Kimura M, Kajita K and Yasuda K: Effect of tumor necrosis factor-alpha on insulin signal transduction in rat adipocytes: Relation to PKCbeta and zeta translocation. Biochim Biophys Acta 1449: 227-238, 1999.
28. Tal R, Pavlovsky L and David M: Psoriasis and cardiovascular risk factors. Harefuah 151: 573-575, 2012 (In Hebrew).
29. Xin-Long C, Zhao-Fan X, Dao-Feng B and Wei D: mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine (307) residues after burn. Burns 37: 86-93, 2011.
30. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF and Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271: 665-668, 1996.
31. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jenkinson C, Jhingan RM, et al: Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: A new mechanism of insulin resistance in humans. Diabetologia 52: 2169-2181, 2009.
32. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Cunsolo V, et al: Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115: 3494-3505, 2005.
33. Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, Sbraccia P, Hribal ML, Lauro R and Federici M: Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56: 2541-2546, 2007.
34. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW and Khokha R: Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 176: 721-725, 2006.